Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Value · John Hancock

Classic Value Fund Class C (JCVCX)

Ticker JCVCX · · Holdings as of Jul 31, 2026

Expense ratio
1.86%$186/yr per $10k
5-yr return
+9.6%annualized
1-yr return
+10.2%as of Dec 2025
Net assets
$544.6Mall share classes
Holdings
37

Bottom line

Is JCVCX a good fund? The bottom line

JCVCX is the Class C share class of Classic Value Fund, a managed large value mutual fund from John Hancock.

Annual fees run 1.86% — about $186 a year on every $10,000 invested, more expensive than 96% of large value funds we track.

It returned +10.2% over one year, +9.6% a year over five years, +8.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $545 million in net assets and 37 holdings, its largest position is Baxter International Inc. (6.5%) and the top 10 make up 41.8% of the portfolio.

What to watch

  • Expensive for its category (1.86%)
  • 12b-1 marketing fee of 1% a year

Updated Nov 19, 2026

What JCVCX invests in

To seek long-term growth of capital.

Under normal conditions, the fund invests at least 80% of its net assets in domestic equity securities. The manager seeks to identify companies that it believes are currently undervalued relative to the market, based on estimated future earnings and cash flow. These companies generally have market values at valuation ratios, such as price to book, below the market average defined by the S&P 500 Index. In choosing individual securities, the manager screens a dynamic universe of the 500 largest publicly traded U.S. companies. (As of December 31, 2025, those with market values above approximately $17 billion.) The manager uses fundamental research and proprietary modeling to rank these companies from the cheapest to the most expensive based on current share price relative to estimated long-term earnings power. Focusing on the cheapest-ranked companies, the manager constructs a portfolio…

From the fund's prospectus (filed Feb 25, 2026).

JCVCX performance

Average annual total returns
1 yr5 yr10 yr
JCVCX+10.2%+9.6%+8.1%
Large Value median+13.6%+11.3%+10.2%

Source: Fund prospectus, as of Dec 31, 2025

Full JCVCX performance history →

What JCVCX costs

On a $10,000 investment, JCVCX's 1.86% expense ratio costs about $186 a year. The prospectus estimates $1,994 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.

See the full JCVCX fee table →

JCVCX top 10 holdings

#Holding% of fund
1Baxter International Inc. BAX US6.53%
2Humana Inc. HUM US5.13%
3CVS Health Corporation CVS US4.53%
4Fresenius Medical Care AG FMS US4.12%
5Dollar General Corporation DG US3.75%
6MetLife Inc. MET US3.75%
7Corebridge Financial Inc. CRBG US3.59%
8Global Payments Inc. GPN US3.51%
9Wells Fargo and Company WFC US3.45%
10Magna International Inc. MGA US3.40%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 41.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to JCVCX

More funds like JCVCX →

JCVCX FAQ

What is the expense ratio of JCVCX?
JCVCX's expense ratio is 1.86%, which works out to about $186 a year for every $10,000 invested. The prospectus estimates total costs of $1,994 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is JCVCX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.86%); 12b-1 marketing fee of 1% a year. This is general information, not personalized advice.
What does JCVCX hold?
JCVCX's largest holdings are Baxter International Inc. (6.5%), Humana Inc. (5.1%), CVS Health Corporation (4.5%), Fresenius Medical Care AG (4.1%), Dollar General Corporation (3.8%). It holds 37 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is JCVCX's 5-year return?
JCVCX returned +9.6% a year over the five years ending Dec 31, 2025, and +8.1% a year over ten years. Past performance does not guarantee future results.
Who manages JCVCX?
JCVCX is offered by John Hancock through John Hancock Capital Series.